NSE filing, NSE: CELLPOINT. Summary written from the filing by ALFA Finder's alert engine.
Cell Point (India) Ltd: key numbers
- Share price
- ₹15.95
- Market cap
- ₹29.80 Cr
- Revenue (annual)
- ₹367.9 Cr
- Net profit (annual)
- ₹0.06 Cr
- P/E (TTM)
- 469.4×Sector 62.0×
- Promoter holding
- 73.06%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cell Point (India) Ltd
All →Cell Point (India) Annual General Meeting
Cell Point (India) Limited conducted its 13th Annual General Meeting on September 29, 2026. Shareholders considered resolutions for adoption of financial statements and director re-appointments.
Cell Point (India) Annual Report
Cell Point (India) Limited issued a corrigendum to its FY 2025-26 Annual Report, including the previously omitted Form AOC-2. The revised report is available online.
Cell Point (India) Annual General Meeting
Cell Point (India) Limited has scheduled its 13th Annual General Meeting for September 29, 2026. The company fixed September 22, 2026, as the record date for voting.
Cell Point (India) Management Change
Cell Point (India) Limited announced the re-appointment of Mr. Mohan Prasad Panday as Managing Director and Mr. Bala Balaji Panday as Whole Time Director for five years.
- Execution
- 5 years
Cell Point (India) Board Meeting Outcome
Cell Point (India) Limited approved the notice for its 13th AGM and the re-appointment of directors during its board meeting.
Cell Point (India) Financial Results
Cell Point (India) Ltd resubmitted its unaudited half‑year 2025 financial results and clarified EPS discrepancies. The submission satisfies the exchange's clarification request.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.